Table 2 Patient demographics and baseline characteristics

From: ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial

 

Physician Choice (N = 41)

ChemoID Guided (N = 40)

p-value

Age

54.6 (10.8)

55.3 (11.9)

0.709

Race

 Asian

28 (68%)

30 (75%)

0.897

 Black

1 (2%)

0 (0%)

 Hispanic

3 (7%)

2 (5%)

 White

9 (22%)

8 (20%)

Baseline CA125

1140 (1740)

1308 (1294)

0.125

# of Prior Platinum Treatments

 1

22 (54%)

20 (50%)

0.599

 2

13 (32%)

13 (33%)

 3

2 (5%)

5 (12%)

 4

4 (8%)

2 (5%)

ECOG

 0

5 (12%)

4 (10%)

>0.999

 1

35 (85%)

36 (90%)

 2

1 (2%)

0 (0%)

Median TFIp (months)

21.0

20.0